9969 Stock Overview
A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
InnoCare Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$6.67 |
| 52 Week High | HK$7.92 |
| 52 Week Low | HK$4.03 |
| Beta | 1.02 |
| 11 Month Change | 1.37% |
| 3 Month Change | 30.02% |
| 1 Year Change | 7.41% |
| 33 Year Change | -63.31% |
| 5 Year Change | n/a |
| Change since IPO | -50.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9969 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 6.9% | 2.5% | 1.4% |
| 1Y | 7.4% | -7.5% | 14.9% |
Return vs Industry: 9969 exceeded the Hong Kong Biotechs industry which returned -12.4% over the past year.
Return vs Market: 9969 underperformed the Hong Kong Market which returned 13.1% over the past year.
Price Volatility
| 9969 volatility | |
|---|---|
| 9969 Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 9969 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9969's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1,109 | Jasmine Cui | www.innocarepharma.com |
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma.
InnoCare Pharma Limited Fundamentals Summary
| 9969 fundamental statistics | |
|---|---|
| Market cap | HK$14.21b |
| Earnings (TTM) | -HK$401.72m |
| Revenue (TTM) | HK$961.68m |
12.2x
P/S Ratio-29.3x
P/E RatioIs 9969 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9969 income statement (TTM) | |
|---|---|
| Revenue | CN¥898.92m |
| Cost of Revenue | CN¥125.58m |
| Gross Profit | CN¥773.34m |
| Other Expenses | CN¥1.15b |
| Earnings | -CN¥375.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 86.03% |
| Net Profit Margin | -41.77% |
| Debt/Equity Ratio | 20.9% |
How did 9969 perform over the long term?
See historical performance and comparison